OncoMed Pharmaceuticals, Inc.

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. To date, we have advanced ten novel anti-cancer product candidates into more than 15 IND’s, initiated 28 clinical studies and have enrolled more than 1,300 subjects. We continue to pursue the discovery of additional novel anti-cancer therapeutics. All of our product candidates were discovered internally in our own research laboratories


Bank Name OncoMed Pharmaceuticals, Inc.
Stock Exchange NASDAQ
Symbol OMED
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
Chairman Mr. Perry A. Karsen
CEO Dr. John A. Lewicki
Employees 56
Website www.oncomed.com
Registered Year 2004